PMID- 26969107
OWN - NLM
STAT- MEDLINE
DCOM- 20170109
LR  - 20220419
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 101
DP  - 2016 May
TI  - Correlation between PD-L1 expression and outcome of NSCLC patients treated with 
      anti-PD-1/PD-L1 agents: A meta-analysis.
PG  - 75-85
LID - S1040-8428(16)30047-6 [pii]
LID - 10.1016/j.critrevonc.2016.03.007 [doi]
AB  - BACKGROUND: A meta analysis of the correlation between PD-L1 levels and outcomes 
      of PD-1/PD-L1 inhibitors in advanced non small cell lung cancer (NSCLC) has been 
      performed. METHODS: Eligible studies included those evaluating PD-1/PD-L1 
      inhibitors in advanced NSCLC and correlating the outcomes to PD-L1 levels. 
      RESULTS: The search strategy yielded 250 potentially relevant citations from 
      searched databases. After preclusion of ineligible studies, 12 studies were 
      included. Comparing PD-1/PD-L1 inhibitors to docetaxel in second line treatment, 
      the pooled hazard ratio (HR) for progression free survival (PFS) and overall 
      survival (OS) was 0.75 (95% CI 0.62-0.90; p=0.002) and 0.61 (95% CI 0.50-75; 
      p=0.00001) respectively; while the pooled odds ratio (OR) for objective response 
      rate (ORR) was 1.98 (95% CI 1.28-3.07; p=0.002) in the PD-L1>1% population. 
      Moreover, for PD-L1>1% patients versus PD-L1<1% patients treated with PD-1/PD-L1 
      targeted agents, the OR of ORR was 2.18 (95% CI 1.45-3.29; p=0.0002); while for 
      PD-L1>5% patients versus PD-L1<5% patients, it was 2.66 (95% CI 1.74-4.07; 
      p<0.00001); and for PD-L1>10% versus PD-L1<10% patients, it was 3.38 (95% CI 
      2.23-5.13; p<0.00001); and for PD-L1>50% versus PD-L1<50% patients, it was 3.99 
      (95% CI 2.81-5.66; p<0.00001). CONCLUSIONS: The current analysis of data 
      indicates that the benefit from PD-1 inhibitors versus docetaxel in second line 
      treatment of NSCLC is limited to the PD-L1>1% subpopulation. Moreover, a possible 
      dose effect relationship between the intensity of PD-L1 staining and the 
      potential benefit from PD-1/PD-L1 targeted agents does exist with higher 
      intensity associated with higher ORR.
CI  - Copyright (c) 2016 Elsevier Ireland Ltd. All rights reserved.
FAU - Abdel-Rahman, Omar
AU  - Abdel-Rahman O
AD  - Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Lotfy 
      Elsayed Street, 11331 Cairo, Egypt. Electronic address: 
      omar.abdelrhman@med.asu.edu.eg.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20160306
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Antineoplastic Agents)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (CD274 protein, human)
RN  - 0 (Taxoids)
RN  - 15H5577CQD (Docetaxel)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - B7-H1 Antigen/*antagonists & inhibitors/*metabolism
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism
MH  - Disease-Free Survival
MH  - Docetaxel
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/metabolism
MH  - Taxoids/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - NSCLC
OT  - Nivolumab
OT  - PD-1
OT  - PD-L1
OT  - Pembrolizumab
EDAT- 2016/03/13 06:00
MHDA- 2017/01/10 06:00
CRDT- 2016/03/13 06:00
PHST- 2015/11/24 00:00 [received]
PHST- 2015/12/23 00:00 [revised]
PHST- 2016/03/03 00:00 [accepted]
PHST- 2016/03/13 06:00 [entrez]
PHST- 2016/03/13 06:00 [pubmed]
PHST- 2017/01/10 06:00 [medline]
AID - S1040-8428(16)30047-6 [pii]
AID - 10.1016/j.critrevonc.2016.03.007 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2016 May;101:75-85. doi: 
      10.1016/j.critrevonc.2016.03.007. Epub 2016 Mar 6.